๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Binzhou
Clinical trial register · China

Clinical Trials in Binzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Qilu Hospital of Shandong University3 Eli Lilly and Company3 TJ Biopharma Co., Ltd.2 Novartis Pharmaceuticals2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Binzhou

28 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Binzhou, Chengdu, Deyang, Ganzhou, Guangzhou, Haikou, Hangzhou, Huaian
2026-06-29
Recruiting
Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients
NCT07574502Colorectal Cancer (CRC)
Sir Run Run Shaw Hospital
Not applicable
190
Binzhou, Hangzhou
2026-06-14
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Binzhou, Chengdu, Guangzhou, Hangzhou, Hengyang, Huizhou, Huzhou, Meihekou
2026-04-29
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642Severe Asthma
DrugTezepelumab
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
NCT06862206Chronic Obstructive Pulmonary Disease
AstraZeneca
Observational
1,000
Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou
2025-07-11
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
DrugsFurmonertinib Mesilate·Furmonertinib
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Not yet open
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647HBV, Chronic Hepatitis b
DrugIFN-ฮฑ
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
DrugIparomlimab and Tuvonralimab
Qilu Hospital of Shandong University
Phase 2
77
Zhengzhou, Binzhou, Dezhou, Dongying, Jinan, Jining, Liaocheng, Linyi
2025-03-26
Active, closed
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336Non Small Cell Lung Cancer
DrugsUliledlimab·Sintilimab·Pemetrexed·Gemcitabine
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Haโ€™erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Active, closed
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532SCLC
DrugsTopotecan·Pumitamig·Paclitaxel
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
NCT06730373HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
DrugsTegafur Gimeracil Oteracil·Disitamab Vedotin·Trastuzumab·Ivonescimab
Qilu Hospital of Shandong University
Phase 2
110
Zhengzhou, Binzhou, Dongying, Jinan, Jining, Liaocheng, Linyi, Qingdao
2024-10-17
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
NCT06662071Bladder Cancer
Qilu Hospital of Shandong University
Observational
293
Binzhou, Dezhou, Jinan, Jining, Liaocheng, Linyi, Qingdao, Taian
2024-10-01
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
NCT06413953Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Active, closed
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588Non Small Cell Lung Cancer
DrugsUliledlimab·Toripalimab·Pembrolizumab
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D
NCT06247046Irritable Bowel Syndrome With Diarrhea
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase 3
1,298
Wuxi, Binzhou
2024-03-16
Recruiting
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
NCT06171061Chronic Coronary Syndrome
DrugYangxinshi
Shandong First Medical University
Phase 4
1,200
Chongqing, Zhengzhou, Binzhou, Dezhou, Feicheng, Jinan, Liaocheng, Linqing
2023-12-18
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Anastrozole·Exemestane
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/binzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Binzhou.

How many clinical trials are recruiting in Binzhou?

21 of the 28 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Binzhou), 28 studies
PhaseStudiesRecruitingShare
Phase 312842.9%
Phase 29832.1%
Observational3210.7%
Not applicable113.6%
Phase 1113.6%
Phase 2/3103.6%
Phase 4113.6%

Most active sponsors

Lead sponsors with the most studies (Binzhou)
Lead sponsorStudiesRecruiting
AstraZeneca65
Eli Lilly and Company33
Qilu Hospital of Shandong University33
Novartis Pharmaceuticals21
TJ Biopharma Co., Ltd.20
Beijing 302 Hospital10
Beijing Continent Pharmaceutical Co, Ltd.11
Biotheus Inc.10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11
Evopoint Biosciences Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.